Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Liposome composition for use in peritoneal dialysis

a technology of liposomes and compositions, applied in the field of liposome compositions for use in peritoneal dialysis, can solve the problems of ammonia toxicity, only available mechanisms, and ammonia toxicity

Inactive Publication Date: 2019-04-11
ETH ZZURICH
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Of course, this mechanism is only available for drugs with sufficient lipophilicity and depends on the extraction coefficient of the drug in the lipid composition.
When present in high concentration ammonia is toxic.
A variety of environmental causes and medications may also lead to ammonia toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liposome composition for use in peritoneal dialysis
  • Liposome composition for use in peritoneal dialysis
  • Liposome composition for use in peritoneal dialysis

Examples

Experimental program
Comparison scheme
Effect test

example 1

Composition and Preparation

[0104]The formulation tested in the following experiments in vivo was composed of DPPC with 45 mol % of CHOL and 5 mol % of DSPE-PEG. The aqueous solution within the liposomes was a 250 mM sodium citrate solution buffered at pH 2. The formulations were prepared by the lipid film hydration / extrusion method (Hope M, Bally M, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985, 55-65). Lipids, CHOL, and eventually the Cholesteryl BODIPY® FL-C12 dye, from Invitrogen (0.05 mol %) were dissolved in chloroform which was subsequently removed under continuous nitrogen flow and high vacuum for >12 h. The lipid film was hydrated with citrate buffer (250 mM, pH 2). The large vesicles were obtained by extrusion through 2 stacked membranes of 5 μm. The transmembrane pH-gradient was established by dialysis i...

example 2

Drainage from the Peritoneal Space to the Blood after Intraperitoneal Administration

[0105]Sprague-dawley rats (male, 300 g) were lightly anesthetized by isofluran inhalation (2%) and 20 mL of a solution of icodextrin 7.5% containing liposomes (either 250 or 850 nm of diameter) bearing the non-exchangeable sterol dye (Cholesteryl BODIPY® FL-C12, Invitrogen, 0.05 mol %) in their membrane were slowly injected in the peritoneal space through sterile puncture. Then, blood aliquots of 250 uL were sampled through the tail veins at 15 min, 1, 2, 4, 6, 8, 10, 12, 14, 16 h after i.p. injection. Plasma was separated from the blood aliquots by centrifugation (6000 g for 10 min) and the dye fluorescence measured in plasma at λem=520 nm (λex=470 nm).

example 3

Ammonia Uptake by pH-Gradient Liposomes in 50% Fetal Bovine Serum

[0106]Ammonia (NH3) uptake kinetics were monitored in 50% FBS in side-by-side diffusion cells (PermGear, Hellertown, Pa.) at 37° C. The liposomes used in this experiment had a diameter of 850 nm and contained 54 mol % DPPC, 45 mol % of cholesterol, and 1 mol % of DSPE-PEG, and an internal citrate solution (250 mM) buffered at pH 2. The donor compartment (liposome-free) was separated from the receiver compartment (containing liposomes) by a polycarbonate membrane with 100 nm pores. The NH3-to-lipid molar ratio was set to 0.45 with an initial NH3 concentration of 1.7 mM in both cells to achieve equilibrium. NH3 uptake by the vesicles in the receiver compartment was directly related to the reduction of toxin concentration in the donor cell. Aliquots of 100 μL were sampled from the donor compartment 3, 30 min, 1, 2, 4, 8, and 24 h after injection of pH-gradient liposomes in the receiver compartment. NH3 was then quantified...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.

Description

[0001]The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the peritoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.BACKGROUND OF THE INVENTION[0002]In order to alter th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/127A61M1/28
CPCA61K9/127A61M1/287A61K9/1271A61K9/1272A61K9/1273A61P19/06A61P3/00A61P39/00A61P39/02A61P7/00A61P7/08A61K2121/00
Inventor LEROUX, JEAN-CHRISTOPHEFORSTER, VINCENT
Owner ETH ZZURICH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com